Anti Tuberculosis Therapeutics Market Report and Forecast 2024-2032

Anti Tuberculosis Therapeutics Market Report and Forecast 2024-2032


Anti Tuberculosis Therapeutics Market Report and Forecast 2024-2032

Anti Tuberculosis Therapeutics Market Outlook

The anti-tuberculosis therapeutics market size was valued at USD 1,354 million in 2023, driven by the rise of multidrug-resistant TB strains in the major markets. The market size is anticipated to grow at a CAGR of 7.6% during the forecast period of 2024-2032 to achieve a value of USD 2589.8 million by 2032.

Tuberculosis: Introduction

Tuberculosis (TB) therapeutics involve a regimen of antibiotics to effectively treat TB, a contagious bacterial infection caused by Mycobacterium tuberculosis. Treatment usually requires a long-term course of multiple antibiotics to ensure complete eradication of the bacteria and prevent resistance. Common drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. Monitoring and adherence to the treatment plan are crucial for success, as improper use can lead to drug-resistant strains, making the disease harder to treat.

Key Trends in the Anti Tuberculosis Therapeutics Market

There is an ongoing effort to develop new and more effective drugs to combat TB, especially drug-resistant strains. The market is witnessing the introduction of novel drug candidates and combination therapies aimed at reducing treatment duration and improving patient outcomes.

With the rise of multidrug-resistant TB strains, there's an increased focus on developing treatments specifically targeting these strains. Pharmaceutical companies and research institutions are investing in the development of drugs that can effectively treat MDR-TB and extensively drug-resistant TB (XDR-TB).

Governments and international organizations are providing financial support for research and development in TB therapeutics. This includes funding for clinical trials to test new drugs and treatment regimens.

Collaborations between governments, non-profit organizations, and pharmaceutical companies are becoming more common to pool resources and expertise in the fight against TB. These partnerships aim to accelerate drug development and ensure access to treatment in low- and middle-income countries.

Healthcare providers are increasingly adopting patient-centered approaches to ensure adherence to TB treatment regimens. This includes the use of digital health tools for monitoring treatment progress and providing support to patients.

International health initiatives, such as the Stop TB Partnership and the Global Fund, play a crucial role in combating TB. These initiatives support drug development, improve access to medicines, and fund programs for TB control and prevention, particularly in regions with high TB prevalence.

Anti Tuberculosis Therapeutics Market Segmentation

Market Breakup by Treatment Type
  • First-Line of Drugs
  • Second-Line of Drugs
  • Others
Market Breakup by Disease Type
  • Active TB
  • Latent TB
  • Others
Market Breakup by Diagnosis
  • Blood Tests
  • Imaging Tests
  • Sputum Tests
  • Others
Market Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Market Breakup by Dosage Form
  • Tablets
  • Capsules
  • Injections
  • Others
Market Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Others
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
Anti Tuberculosis Therapeutics Market Overview

In North America, the anti-tuberculosis therapeutics market is well-established, with a strong emphasis on public health initiatives and advanced healthcare infrastructure. The region has effective TB control programs, ensuring early diagnosis and treatment adherence. There's also a significant focus on research and development of new therapies and drug-resistant TB solutions, supported by government funding and collaborations between healthcare institutions and pharmaceutical companies.

Europe's market benefits from comprehensive healthcare systems and robust TB surveillance and treatment programs. The region is active in addressing drug-resistant TB through research and collaborative European health initiatives. Access to advanced healthcare facilities and a focus on high-quality care contribute to effective TB management. Efforts are also directed towards integrating TB care with services for related conditions like HIV, enhancing overall treatment outcomes.

The market in the Japan region is diverse, efforts to control TB are challenged by factors such as population density, healthcare access, and economic disparities. However, increasing healthcare investment, government initiatives, and international support are enhancing TB diagnosis and treatment. The region also focuses on addressing drug-resistant TB and improving public health education and TB awareness.

Anti Tuberculosis Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis
  • Allergan
  • Merck & Co.
  • STI Pharma
  • Endo International plc
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Tuberculosis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Tuberculosis Epidemiology Analysis – Seven Major Markets
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Tuberculosis Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Tuberculosis Epidemiology Forecast (2017-2032)
5.3.1 Germany Tuberculosis Epidemiology Forecast (2017-2032)
5.3.2 France Tuberculosis Epidemiology Forecast (2017-2032)
5.3.3 Italy Tuberculosis Epidemiology Forecast (2017-2032)
5.3.4 Spain Tuberculosis Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Tuberculosis Epidemiology Forecast (2017-2032)
5.4 Japan Tuberculosis Epidemiology Forecast (2017-2032)
6 Anti Tuberculosis Therapeutics Market Overview – Seven Major Markets
6.1 Anti Tuberculosis Therapeutics Market Historical Value (2017-2023)
6.2 Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
7 Anti Tuberculosis Therapeutics Market Landscape – Seven Major Markets
7.1 Anti Tuberculosis Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Anti Tuberculosis Therapeutics Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by End User
8 Anti Tuberculosis Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Anti Tuberculosis Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Anti Tuberculosis Therapeutics Market Segmentation – Seven Major Markets
11.1 Anti Tuberculosis Therapeutics Market by Treatment Type
11.1.1 Market Overview
11.1.2 First-Line of Drugs
11.1.3 Second-Line of Drugs
11.1.4 Others
11.2 Anti Tuberculosis Therapeutics Market by Disease Type
11.2.1 Market Overview
11.2.2 Active TB
11.2.3 Latent TB
11.2.4 Others
11.3 Anti Tuberculosis Therapeutics Market by Diagnosis
11.3.1 Market Overview
11.3.2 Blood Tests
11.3.3 Imaging Tests
11.3.4 Sputum Tests
11.3.5 Others
11.4 Anti Tuberculosis Therapeutics Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.4.4 Others
11.5 Anti Tuberculosis Therapeutics Market by Dosage Form
11.5.1 Market Overview
11.5.2 Tablets
11.5.3 Capsules
11.5.4 Injections
11.5.5 Others
11.6 Anti Tuberculosis Therapeutics Market by End User
11.6.1 Market Overview
11.6.2 Hospitals
11.6.3 Speciality Clinics
11.6.4 Others
11.7 Anti Tuberculosis Therapeutics Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
12 United States Anti Tuberculosis Therapeutics Market
12.1 Anti Tuberculosis Therapeutics Market Historical Value (2017-2023)
12.2 Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
12.3 Anti Tuberculosis Therapeutics Market by Disease Type
12.4 Anti Tuberculosis Therapeutics Market by Treatment Type
13 EU-4 and United Kingdom Anti Tuberculosis Therapeutics Market
13.1 Anti Tuberculosis Therapeutics Market Historical Value (2017-2023)
13.2 Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
13.3 Germany Anti Tuberculosis Therapeutics Market Overview
13.3.1 Anti Tuberculosis Therapeutics Market by Disease Type
13.3.2 Anti Tuberculosis Therapeutics Market by Treatment Type
13.4 France Anti Tuberculosis Therapeutics Market Overview
13.4.1 Anti Tuberculosis Therapeutics Market by Disease Type
13.4.2 Anti Tuberculosis Therapeutics Market by Treatment Type
13.5 Italy Anti Tuberculosis Therapeutics Market Overview
13.5.1 Anti Tuberculosis Therapeutics Market by Disease Type
13.5.2 Anti Tuberculosis Therapeutics Market by Treatment Type
13.6 Spain Anti Tuberculosis Therapeutics Market Overview
13.6.1 Anti Tuberculosis Therapeutics Market by Disease Type
13.6.2 Anti Tuberculosis Therapeutics Market by Treatment Type
13.7 United Kingdom Anti Tuberculosis Therapeutics Market Overview
13.7.1 Anti Tuberculosis Therapeutics Market by Disease Type
13.7.2 Anti Tuberculosis Therapeutics Market by Treatment Type
14 Japan Anti Tuberculosis Therapeutics Market
14.1 Anti Tuberculosis Therapeutics Market Historical Value (2017-2023)
14.2 Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
14.3 Anti Tuberculosis Therapeutics Market by Disease Type
14.4 Anti Tuberculosis Therapeutics Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 AstraZeneca
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Johnson & Johnson Private Limited
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Eli Lilly and Company
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 F. Hoffmann-La Roche Ltd.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Mylan N.V.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Teva Pharmaceutical Industries Ltd.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Sanofi
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Novartis
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Allergan
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Merck & Co.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 STI Pharma
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Endo International plc
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Fresenius Kabi AG
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Hikma Pharmaceuticals PLC
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
22 Anti Tuberculosis Therapeutics Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings